Gabriella De Carli

Dr. Gabriella De Carli

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1999 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GIGiuseppe Ippolito
Giuseppe Ippolito
VPVincenzo Puro
Vincenzo Puro
JHJulia Heptonstall
Julia Heptonstall
JJJanine Jagger
Janine Jagger
GCGabriella De Carli
Gabriella De Carli
Nicola PetrosilloNicola Petrosillo
Nicola Petrosillo
The average estimated risk of human immunodeficiency virus (HIV) infection for health care workers following a percutaneous or mucous exposure is <

15 November 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YYY. Yazdanpanah
Y. Yazdanpanah
GCGabriella De Carli
Gabriella De Carli
BMB. Migueres
B. Migueres
FLF. Lot
F. Lot
MCM. Campins
M. Campins
EBE. Bouvet
E. Bouvet
Background. Additional studies are required to identify risk factors for hepatitis C virus (HCV) transmission to health care workers after occupation

1 January 2015 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Giuseppe BanfiGiuseppe Banfi
Giuseppe Banfi
SCStephen Church
Stephen Church
MCMichael Cornes
Michael Cornes
GCGabriella De Carli
Gabriella De Carli
OPon behalf of the European Federation for Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase
on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase
Laboratory diagnostics develop through different phases that span from test ordering (pre-preanalytical phase), collection of diagnostic specimens (preanalytical phase), sample analysis (analytical phase), results reporting (postanalytical phase) and interpretation (post-postanalytical phase). Although laboratory medicine seems less vulnerable than other clinical and diagnostic areas, the chance of errors is not negligible and may adversely impact on quality of testing and patient safety. This article, which continues a biennial tradition of collective papers on preanalytical quality improvement, is aimed to provide further contributions for pursuing quality and harmony in the preanalytical phase, and is a synopsis of lectures of the third European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)-Becton Dickinson (BD) European Conference on Preanalytical Phase meeting entitled ‘Preanalytical quality improvement. In pursuit of harmony’ (Porto, 20–21 March 2015). The leading topics that will be discussed include unnecessary laboratory testing, management of test request, implementation of the European Union (EU) Directive on needlestick injury prevention, harmonization of fasting requirements for blood sampling, influence of physical activity and medical contrast media on in vitro diagnostic testing, recent evidence about the possible lack of necessity of the order of draw, the best practice for monitoring conditions of time and temperature during sample transportation, along with description of problems emerging from inappropriate sample centrifugation. In the final part, the article includes recent updates about preanalytical quality indicators, the feasibility of an External Quality Assessment Scheme (EQAS) for the preanalytical phase, the results of the 2nd EFLM WG-PRE survey, as well as specific notions about the evidence-based quality management of the preanalytical phase.

29 March 2016 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
AMAlice Mannocci
Alice Mannocci
GCGabriella De Carli
Gabriella De Carli
VBVirginia Di Bari
Virginia Di Bari
RSRosella Saulle
Rosella Saulle
BUBrigid Unim
Brigid Unim
Giuseppe La TorreGiuseppe La Torre
Giuseppe La Torre
OBJECTIVE: To provide an overview of the economic aspects of needlestick and sharps injury (NSI) management among healthcare personnel (HCP) within a Health Technology Assessment project to evaluate the impact of safety-engineered devices on health careMETHODS: A systematic review of economic analyses related to NSIs was performed in accordance with the PRISMA statement and by searching PubMed and Scopus databases (January 1997–February 2015). Mean costs were stratified by study approach (modeling or data driven) and type of cost (direct or indirect). Costs were evaluated using the CDC operative definition and converted to 2015 International US dollars (Int$).RESULTS: A total of 14 studies were retrieved: 8 data-driven studies and 6 modeling studies. Among them, 11 studies provided direct and indirect costs and 3 studies provided only direct costs. The median of the means for aggregate (direct + indirect) costs was Int$747 (range, Int$199–Int$1,691). The medians of the means for disaggregated costs were Int$425 (range, Int$48–Int$1,516) for direct costs (9 studies) and Int$322 (range, Int$152–Int$413) for indirect costs (6 studies). When compared with data-driven studies, modeling studies had higher disaggregated and aggregated costs, but data-driven studies showed greater variability. Indirect costs were consistent between studies, mostly referring to lost productivity, while direct costs varied widely within and between studies according to source infectivity, HCP susceptibility, and post-exposure diagnostic and prophylactic protocols. Costs of treating infections were not included, and intangible costs could equal those associated with NSI medical evaluations.CONCLUSIONS: NSIs generate significant direct, indirect, potential, and intangible costs, possibly increasing over time. Economic efforts directed at preventing occupational exposures and infections, including provision of safety-engineered devices, may be offset by the savings from a lower incidence of NSIs.Infect Control Hosp Epidemiol 2016;37:635–646

1 October 2005 in Eurosurveillance
Verified
Journal Article
Open access
VPV Puro
V Puro
GCGabriella De Carli
Gabriella De Carli
SCS Cicalini
S Cicalini
FSF Soldani
F Soldani
UBU Balslev
U Balslev
GIGiuseppe Ippolito
Giuseppe Ippolito
Exposure prevention is the primary strategy to reduce the risk of occupational bloodborne pathogen infections in healthcare workers (HCW). HCWs should be made aware of the medicolegal and clinical relevance of reporting an exposure, and have ready access to expert consultants to receive appropriate counselling, treatment and follow-up. Vaccination against hepatitis B virus (HBV), and demonstration of immunisation before employment are strongly recommended. HCWs with postvaccinal anti-HBs levels, 1-2 months after vaccine completion, >10 mIU/mL are considered as responders. Responders are protected against HBV infection: booster doses of vaccine or periodic antibody concentration testing are not recommended. Alternative strategies to overcome non-response should be adopted. Isolated anti-HBc positive HCWs should be tested for anti-HBc IgM and HBV-DNA: if negative, anti-HBs response to vaccination can distinguish between infection (anti-HBs >50 mUI/ml 30 days after 1st vaccination: anamnestic response) and false positive results(anti-HBs >10 mUI/ml 30 days after 3rd vaccination: primary response); true positive subjects have resistance to re-infection. and do not need vaccination The management of an occupational exposure to HBV differs according to the susceptibility of the exposed HCW and the serostatus of the source. When indicated, post-exposure prophylaxis with HBV vaccine, hepatitis B immunoglobulin or both must be started as soon as possible (within 1-7 days). In the absence of prophylaxis against hepatitis C virus (HCV) infection, follow-up management of HCV exposures depends on whether antiviral treatment during the acute phase is chosen. Test the HCW for HCV-Ab at baseline and after 6 months; up to 12 for HIV-HCV co-infected sources. If treatment is recommended, perform ALT (amino alanine transferase) activity at baseline and monthly for 4 months after exposure, and qualitative HCV-RNA when an increase is detected.

14 May 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
VPVincenzo Puro
Vincenzo Puro
APAntonio Palummieri
Antonio Palummieri
GCGabriella De Carli
Gabriella De Carli
PPPierluca Piselli
Pierluca Piselli
GIGiuseppe Ippolito
Giuseppe Ippolito
To investigate perceptions and attitude to prescribe Pre-Exposure Prophylaxis (PrEP) among HIV specialists. A questionnaire developed through a Focus Group and literature review was administered to a convenience sample of HIV specialists during educational courses in two Regions and an online survey in February-May 2012. Participants were classified as having a positive or negative attitude according to their willingness to prescribe PrEP. Demographic and working information, experience with HIV-infected patients, information and provision of antiretrovirals to uninfected persons, self-reported knowledge, perceptions and concerns regarding PrEP were assessed. The association between a different attitude towards PrEP prescription and selected characteristics was assessed through univariate and multivariate regression analysis. Of 311 specialists, 70% would prescribe PrEP, mainly to serodiscordant partners (64%) but also to people at ongoing, high risk of HIV infection (56%); 66% advocated public support of costs. A negative attitude towards PrEP was significantly associated with lack of provision of information on, and prescription of, antiretroviral post-exposure prophylaxis; specialists with a negative attitude believed behavioural interventions to be more effective than PrEP and were more concerned about toxicity. Overall, 90% of specialists disagreed regarding a lack of time for engaging in prevention counselling and PrEP monitoring; 79% would welcome formal guidelines, while those with a negative attitude did not consider this advisable. Although conflicting attitudes appear evident, most specialists seem to be willing, with guidance from normative bodies, to promote PrEP within multiple prevention strategies among vulnerable populations. More scientific evidence regarding effectiveness could overcome resistance.